Switch theme
Sign up to access all valuation multiples
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
2001
15
LTM Revenue n/a
LTM EBITDA n/a
$178M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Galectin Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Galectin Therapeutics achieved revenue of n/a and an EBITDA of -$41.5M.
Galectin Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Galectin Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$38.2M | -$41.5M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$38.8M | -$41.1M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | $21.2M | $46.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Galectin Therapeutics's stock price is $1.
Galectin Therapeutics has current market cap of $84.7M, and EV of $178M.
See Galectin Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $178M | $84.7M | XXX | XXX | XXX | XXX | $-0.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Galectin Therapeutics has market cap of $84.7M and EV of $178M.
Galectin Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Galectin Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Galectin Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $178M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGalectin Therapeutics's NTM/LTM revenue growth is n/a
Galectin Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.8M for the same period.
Over next 12 months, Galectin Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Galectin Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Galectin Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galectin Therapeutics acquired XXX companies to date.
Last acquisition by Galectin Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Galectin Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Galectin Therapeutics founded? | Galectin Therapeutics was founded in 2001. |
| Where is Galectin Therapeutics headquartered? | Galectin Therapeutics is headquartered in United States of America. |
| How many employees does Galectin Therapeutics have? | As of today, Galectin Therapeutics has 15 employees. |
| Who is the CEO of Galectin Therapeutics? | Galectin Therapeutics's CEO is Mr. Joel Lewis. |
| Is Galectin Therapeutics publicy listed? | Yes, Galectin Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Galectin Therapeutics? | Galectin Therapeutics trades under GALT ticker. |
| When did Galectin Therapeutics go public? | Galectin Therapeutics went public in 2002. |
| Who are competitors of Galectin Therapeutics? | Similar companies to Galectin Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Galectin Therapeutics? | Galectin Therapeutics's current market cap is $84.7M |
| Is Galectin Therapeutics profitable? | Yes, Galectin Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
